ScoreComparison
Why is Rigel Pharmaceuticals, Inc. ?
1
With a growth in Net Profit of 860.81%, the company declared Outstanding results in Sep 25
- The company has declared positive results for the last 4 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 68.18 MM
- NET SALES(HY) At USD 171.15 MM has Grown at 85.73%
- NET PROFIT(HY) Higher at USD 87.51 MM
2
With ROE of 96.34%, it has a very attractive valuation with a 4.17 Price to Book Value
- Over the past year, while the stock has generated a return of 27.69%, its profits have risen by 2820.1%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
- Their stake has increased by 12.75% over the previous quarter.
4
Consistent Returns over the last 3 years
- Along with generating 27.69% returns in the last 1 year, the stock has outperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Rigel Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Rigel Pharmaceuticals, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Rigel Pharmaceuticals, Inc.
31.19%
2.19
70.41%
S&P 500
16.12%
0.77
19.29%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
21.72%
EBIT Growth (5y)
44.63%
EBIT to Interest (avg)
-5.21
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
3.31
Tax Ratio
2.48%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
526.12%
ROE (avg)
40.05%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
4
Industry P/E
Price to Book Value
4.17
EV to EBIT
3.48
EV to EBITDA
3.41
EV to Capital Employed
10.14
EV to Sales
1.47
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
291.62%
ROE (Latest)
96.34%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend25What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 68.18 MM
NET SALES(HY)
At USD 171.15 MM has Grown at 85.73%
NET PROFIT(HY)
Higher at USD 87.51 MM
ROCE(HY)
Highest at 220.06%
RAW MATERIAL COST(Y)
Fallen by -9.08% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 7.37 times
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Rigel Pharmaceuticals, Inc.
Net Profit
At USD 87.51 MM has Grown at 668.26%
Year on Year (YoY)MOJO Watch
Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
At USD 171.15 MM has Grown at 85.73%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD 68.18 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
Higher at USD 87.51 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Debtors Turnover Ratio
Highest at 7.37 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -9.08% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
